文摘
摘要目的:检查协会的医源性脑梗塞患者的结果
背景:小医源性脑梗塞通常出现在diffusion-weighted MRI(驾车)手术或血管内过程后,但很少有数据在他们的临床效果。我们检查了医源性梗塞协会制定的结果(在动脉瘤绕线评估神经保护治疗,NCT00728182nerinetide)随机对照试验的患者进行颅内动脉瘤的血管内修复。
设计/方法:在这个因果分析,我们使用多变量模型来评估协会的存在和数量医源性梗塞在酒后神经损伤(美国国立卫生研究院的中风尺度(署)),功能状态(改良Rankin规模(夫人)),认知和神经精神成果(30分钟测试电池)和30需要术后1 - 4天。我们也梗塞相关Z-score-derived复合使用分位数回归结果评分。
结果:在184名患者(平均年龄56岁,差:50 - 64),124(67.4%)术后醉酒驾车病变(平均4,差:2 - 10.5)。Nerinetide整体治疗医源性梗塞较少有关,但没有显著的临床治疗效果。梗塞患者心理状况较低的考试成绩(MMSE) 2 - 4天(中位数:28日和29日adjusted-coefficient [acoef]:−1.11, 95%置信区间ci: 1.88−−0.34, p = 0.005)。更高的病变数量与糟糕的普通人署(优势比为署≥1:1.07,1.02 - -1.12,p = 0.009),一天2 - 4夫人(调整后常见的优势比(aOR): 1.05, 1.01 - -1.09, p = 0.005),和2 - 4天MMSE (acoef:−0.07−0.13−0.003, p = 0.040)。夫人在30,梗塞相关数量仍然较差(优势比:1.04,1.01 - -1.07,p = 0.016)和霍普金斯言语学习测试(HVLT)延迟回忆分数(acoef:−0.21−0.39−0.03, p = 0.020)。病灶数高,更糟糕的是复合结果分数在1 - 4天,30天(30 acoef: 0.12−−0.21−0.03, p = 0.008)。那些梗塞,普通人署和2 - 4天与30天署,夫人HVLT,和夫人分数,而一天2 - 4 MMSE与30天署分数(Spearman-Rho: 0.47, p = 0.001)。
结论:在术后医源性脑梗塞与细微的差别有关(1 - 4天)和30天的结果在不同的措施在这个中年人群,与早期功能障碍相关与后来的差异。
披露:Ganesh博士已经收到个人薪酬在500 - 4999美元的范围作为顾问MD分析。Ganesh博士已经收到个人薪酬在500 - 4999美元的范围为MyMedicalPanel担任顾问。Ganesh博士已经收到个人薪酬在500 - 4999美元的范围作为Adkins研究小组的顾问。Ganesh博士已经收到个人补偿的范围0 - 499美元为图1作为顾问。Ganesh博士已经收到个人补偿的范围0 - 499美元为DeepBench担任顾问。Ganesh博士已经收到个人补偿的范围为0 - 499美元作为一个编辑,副主编、编辑顾问委员会成员对美国神经学学院(期刊神经病学和神经学:临床实践)。首页Ganesh博士已经收到个人补偿的范围为0 - 499美元作为一个编辑,副主编、编辑顾问委员会成员为美国心脏协会(日报:中风)。Ganesh博士接到SnapDx股票或所有权权益。Ganesh博士获得了股票或所有权的兴趣TheRounds.com。Ganesh博士已经收到了来自先进的健康分析股票或所有者权益(啊哈健康有限公司)。Ganesh博士的机构已经接到加拿大健康研究院的研究支持。Ganesh博士的机构收到加拿大心血管研究支持的社会。Ganesh博士的机构已经接到艾伯塔创新研究支持。Ganesh已收到博士研究的机构来自卡尔加里大学的临床研究中心的支持。Ganesh博士的机构已收到研究支持创新4健康。Ganesh博士的机构收到INOVAIT新宁研究所的研究支持。Ganesh博士的机构已收到从校园阿尔伯塔省神经科学研究支持。Ganesh博士收到发现或技术知识产权利益有关卫生保健。 Dr. Wilson has nothing to disclose. The institution of Dr. Ospel has received personal compensation in the range of $0-$499 for serving as a Consultant for GE Healthcare. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lumosa. Dr. Demchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pfizer/BMS. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer Ingelheim. Dr. Demchuk has received stock or an ownership interest from Circle NVI. Dr. Demchuk has received intellectual property interests from a discovery or technology relating to health care. Dr. Mikulis has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Neinstein Personal Injury Lawyers. Dr. Mikulis has received stock or an ownership interest from Thornhill Medical, Inc.. Dr. Mikulis has received intellectual property interests from a discovery or technology relating to health care. Dr. Anderson has received personal compensation for serving as an employee of Syneos Health. Dr. Anderson has received stock or an ownership interest from Syneos Health. Michael Tymianski, MD, PHD, FRCSC has received personal compensation for serving as an employee of NoNO Inc.. Michael Tymianski, MD, PHD, FRCSC has received stock or an ownership interest from NoNO Inc. Dr. Hill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Dr. Hill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sun Pharma. Dr. Hill has received stock or an ownership interest from Circle Neurovascular.
